Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo for ribavirin Clear all
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01225380
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Terminated Phase 2 Interventional Results available

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

NCT04605588
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

NCT01289782
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

NCT00703118
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Tibotec BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

NCT01434498
View directory record Official record
Conditions
Chronic Genotype 1a or 1b HCV Infection
Interventions
GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule
Drug · Device
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Beverly Hills, California • Coronado, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

NCT00420784
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
24
States / cities
La Jolla, California • Long Beach, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

CTS-1027 in Interferon-Naive Hepatitis C Patients

NCT00925990
View directory record Official record
Conditions
Hepatitis C
Interventions
ribavirin, CTS-1027, Placebo for ribavirin
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

NCT01054573
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV)
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Coronado, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects

NCT01445795
View directory record Official record
Conditions
Hepatitis C
Interventions
200 mg INX-08189 Fasted, Placebo QD Fasted, 100 mg INX-08189 QD, Placebo QD, 100 mg INX-08189 with low-fat meal, Placebo with low-fat meal, 100 mg INX-08189 BID Fasted, Placebo BID Fasted, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

NCT01604850
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Placebo to match SOF, Placebo to match RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
51
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

NCT01278134
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

NCT00720434
View directory record Official record
Conditions
Hepatitis C
Interventions
PF-00868554, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2013 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 1 Interventional Results available

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

NCT00793793
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI201335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679
View directory record Official record
Conditions
Hepatitis C
Interventions
Placebo, TMC435, Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

NCT01281839
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT00851890
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
ABT-333, Placebo for ABT-333, Pegylated interferon, Ribavirin
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Anaheim, California • Los Angeles, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

NCT00637923
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Nitazoxanide, Placebo, Peginterferon alfa-2a, Ribavirin
Drug · Biological
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Palo Alto, California • New Haven, Connecticut • Bay Pines, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 1, 2026, 2:50 PM EDT
Completed Phase 3 Interventional

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

NCT01323244
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Bakersfield, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 1, 2026, 2:50 PM EDT